Loading
A phase 3 trial of Tunlametinib run by Shanghai Kechow Pharma, Inc. in colorectal cancer, now recruiting.
Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer is a phase 3 interventional study registered as NCT06008119 by Shanghai Kechow Pharma, Inc., with 165 participants planned, started 2023-10-25. Conditions listed: Colorectal Cancer Metastatic. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Shanghai Kechow Pharma, Tunlametinib, Small-molecule kinase inhibitors.
Shares BRAF V600E-mutant colorectal cancer, Small-molecule kinase inhibitors, Colorectal cancer.
Shares BRAF V600E-mutant colorectal cancer, Small-molecule kinase inhibitors.
Shares BRAF V600E-mutant colorectal cancer, Small-molecule kinase inhibitors.
Shares BRAF V600E-mutant colorectal cancer, Small-molecule kinase inhibitors.
Shares BRAF V600E-mutant colorectal cancer, Small-molecule kinase inhibitors.
Shares BRAF V600E-mutant colorectal cancer, Small-molecule kinase inhibitors, Colorectal cancer.
Shares BRAF V600E-mutant colorectal cancer, Small-molecule kinase inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/